IPP Bureau
Symeres rehires Jurgen Berendsen as CFO amid strategic growth push
By IPP Bureau - January 20, 2026
Berendsen brings over 15 years of financial leadership experience spanning professional services and international trade
IDT and Ansa Biotechnologies join forces to push limits of DNA synthesis
By IPP Bureau - January 20, 2026
The collaboration aims to accelerate the delivery of challenging DNA motifs with speed, precision, and reliability
China nod to two Sanofi drugs for rare and complex conditions
By IPP Bureau - January 20, 2026
Myqorzo, a selective small-molecule cardiac myosin inhibitor, is designed to improve functional capacity and relieve symptoms in oHCM
AbbVie’s Epcoritamab shows progression-free survival gain in relapsed/refractory DLBCL trial
By IPP Bureau - January 20, 2026
Improvements were also seen in complete response rates, duration of response, and time to next treatment
China nod to first homegrown BNCT cancer drug for human trials
By IPP Bureau - January 20, 2026
The injectable borofalan (10B), developed by CNNC Headway—a subsidiary of China Isotope & Radiation Corporation (CIRC) under the China National Nuclear Corporation (CNNC)—has officially entered Phase I clinical trials
AGC Biologics powers commercial launch of its life-changing gene therapy for rare childhood immune disorder
By IPP Bureau - January 20, 2026
Waskyra is an ex vivo gene therapy that uses patients’ own CD34+ hematopoietic stem and progenitor cells, genetically engineered with a lentiviral vector
DNA Nanorobots & AI could slash drug development times, Nanovery CEO says
By IPP Bureau - January 20, 2026
DNA nanorobots—tiny, self-assembling machines capable of detecting diseases in blood samples within 2–4 hours
Syngene locks in Bristol Myers Squibb alliance through 2035
By IPP Bureau - January 20, 2026
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
Mahajan Imaging & Labs launches AI-driven blood test to detect Alzheimer’s early
By IPP Bureau - January 20, 2026
Over 8.8?million Indians aged 60 and above currently live with dementia,
Manthan 2026 wraps up, spotlighting India’s life sciences & clinical research future
By IPP Bureau - January 20, 2026
India in the Changing Landscape of Life-Sciences Research & Development
IRLAB Therapeutics teams up with Biomia to advance novel CNS drug candidates
By IPP Bureau - January 20, 2026
BorderPlus unveils AI-powered nurse companion at German Nursing Career Fair in Kochi
By IPP Bureau - January 20, 2026
The AI Nurse Companion, designed as a language-first learning platform, allows students to gain real-world German language proficiency through immersive practice
Torrent Pharma secures Rs. 12,500 crore for JB Chemicals takeover
By IPP Bureau - January 18, 2026
The capital was raised via multiple-tenure non-convertible debentures (NCDs) and commercial papers
JB Pharma Q3 FY26 PAT up by 22% to Rs. 198 Cr
By IPP Bureau - January 18, 2026
The company recorded revenue of Rs. 1,065 crore in the third quarter of FY26
Bayer welcomes the U.S. Supreme Court decision to review Durnell case in the Roundup litigation
By IPP Bureau - January 17, 2026
Favorable outcome would contribute to significantly containing the Roundup litigation as the company continues its multi-pronged strategy
